Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 Antibody

Next Previous
Trial Profile

A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 Antibody

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGB A445 (Primary) ; BGB-15025 (Primary) ; Docetaxel (Primary) ; Ramucirumab (Primary) ; Sitravatinib (Primary) ; Tislelizumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors BeiGene

Most Recent Events

  • 22 May 2025 According to the BeiGene media release, final analysis from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 -June 3, 2025.
  • 10 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 20 Oct 2024 New source identified and integrated (China Drug Trials;CTR20233070).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top